# Evrenzo® (roxadustat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/roxadustat

> The next catalyst for Evrenzo® (roxadustat), sponsored by KYNTRA BIO, INC. (KYNB), is its primary completion, September 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Evrenzo® (roxadustat) |
| Codes | FG-4592 |
| Sponsor | KYNTRA BIO, INC. (KYNB) https://sec-api.dev/companies/kynb/catalysts |
| Indications | anemia in patients with lower-risk myelodysplastic syndromes, anemia in patients with lr-mds, [Myelodysplastic Syndromes](https://sec-api.dev/indications/myelodysplastic-syndromes) |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### May 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0000950170-24-125388): "In May 2023, we announced positive topline data from our Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies in China." https://www.sec.gov/Archives/edgar/data/921299/000095017024125388/fgen-20240930.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: anemia in patients with LR-MDS.
- First seen 2026-03-16, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349141): "Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349141): "Company continues to explore the opportunity to develop roxadustat internally or with a strategic partner, with the goal of initiating the Phase 3 trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-216731): "Company continues to explore the opportunity to develop roxadustat internally or with a strategic partner, with the goal of initiating the Phase 3 trial in the second half of 2026" https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-108324): "Additionally, we have submitted the Phase 3 trial protocol for roxadustat for the treatment of anemia in patients with LR-MDS and expect feedback from the FDA shortly, with the intention to start a Phase 3 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-108324): "Company is currently exploring the opportunity to develop roxadustat internally or with a strategic partner, with the goal of starting the Phase 3 trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07722988 (A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Kyntra Bio." https://clinicaltrials.gov/study/NCT07722988

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07722988 (A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Kyntra Bio." https://clinicaltrials.gov/study/NCT07722988

## Same indication

- [Decitabine](https://sec-api.dev/pdufa/decitabine) (NVS)
- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [Luspatercept](https://sec-api.dev/pdufa/luspatercept) (BMY)
- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib) (GSK)
- [Oral azacitidine](https://sec-api.dev/pdufa/oral-azacitidine) (BMY)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/roxadustat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Evrenzo® (roxadustat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/roxadustat

```bibtex
@misc{secapidev_pdufa_roxadustat_20261116,
  title        = {Evrenzo® (roxadustat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/roxadustat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_roxadustat_20261116","title":"Evrenzo® (roxadustat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/roxadustat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
